
Opinion|Videos|June 26, 2024
Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, from Mayo Clinic opens a conversation around CDK4/6 inhibitor prescription for patients diagnosed with early breast cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In the adjuvant treatment of HR-positive/HER2-negative early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years.
- What factors related to the patient or disease influences your decision to prescribe a CDK4/6 inhibitor in this setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
2
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
3
Digital Innovation and New Drugs Converge to Transform CRM Care
4
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
5








































